Skip to Main Content

Paper Details

CAR T cells produced in vivo to treat cardiac injury.
Science
368
2022
Antifibrotic CAR T cells, CAR, CAR T cells, CD5, Fibrosis, LNPs, T lymphocytes, antifibrotic, cardiac disease, cardiac injury, chimeric antigen receptor, chimeric antigen receptor (CAR) T cells, heart failure, in vivoreprogrammed CAR T cells, mRNA, modified mRNA, modified messenger RNA, mouse, people
Author NameAffiliation
Carl H JuneCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania
Drew WeissmanPerelman School of Medicine at the University of Pennsylvania
  • 1 - 2

Datasets

Release 1.2